Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 325

1.

Regional variation of Guillain-Barré syndrome.

Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L, van den Bergh P, Casasnovas C, Cavaletti G, Chavada G, Claeys KG, Dardiotis E, Davidson A, van Doorn PA, Feasby TE, Galassi G, Gorson KC, Hartung HP, Hsieh ST, Hughes RAC, Illa I, Islam B, Kusunoki S, Kuwabara S, Lehmann HC, Miller JAL, Mohammad QD, Monges S, Nobile Orazio E, Pardo J, Pereon Y, Rinaldi S, Querol L, Reddel SW, Reisin RC, Shahrizaila N, Sindrup SH, Waqar W, Jacobs BC; IGOS Consortium .

Brain. 2018 Oct 1;141(10):2866-2877. doi: 10.1093/brain/awy232.

PMID:
30247567
2.

Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain.

Bechakra M, Nieuwenhoff MD, van Rosmalen J, Groeneveld GJ, Scheltens-de Boer M, Sonneveld P, van Doorn PA, de Zeeuw CI, Jongen JL.

Mol Pain. 2018 Jan-Dec;14:1744806918797042. doi: 10.1177/1744806918797042.

3.

Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.

Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, Cornblath DR, van Doorn PA; Dutch GBS Study Group.

J Peripher Nerv Syst. 2018 Aug 27. doi: 10.1111/jns.12286. [Epub ahead of print]

PMID:
30151941
4.

Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a phase II safety and feasibility study.

Islam B, Islam Z, Rahman S, Endtz HP, Vos MC, van der Jagt M, van Doorn PA, Jacobs BC, Mohammad QD.

BMJ Open. 2018 Aug 17;8(8):e022862. doi: 10.1136/bmjopen-2018-022862.

5.

Advances in management of Guillain-Barré syndrome.

Doets AY, Jacobs BC, van Doorn PA.

Curr Opin Neurol. 2018 Oct;31(5):541-550. doi: 10.1097/WCO.0000000000000602.

PMID:
30074496
6.

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients.

van der Meijden JC, Kruijshaar ME, Rizopoulos D, van Doorn PA, van der Beek NAME, van der Ploeg AT.

Orphanet J Rare Dis. 2018 May 22;13(1):82. doi: 10.1186/s13023-018-0824-4.

7.

A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.

Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA.

J Peripher Nerv Syst. 2018 Jun;23(2):108-114. doi: 10.1111/jns.12267. Epub 2018 Apr 26.

8.

Imaging of respiratory muscles in neuromuscular disease: A review.

Harlaar L, Ciet P, van der Ploeg AT, Brusse E, van der Beek NAME, Wielopolski PA, de Bruijne M, Tiddens HAWM, van Doorn PA.

Neuromuscul Disord. 2018 Mar;28(3):246-256. doi: 10.1016/j.nmd.2017.11.010. Epub 2017 Nov 24. Review.

PMID:
29398294
9.

Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study).

Kuitwaard K, Fokkink WR, Brusse E, Vrancken AFJE, Eftimov F, Notermans NC, van der Kooi AJ, Merkies ISJ, Jacobs BC, van Doorn PA.

J Peripher Nerv Syst. 2018 Mar;23(1):5-10. doi: 10.1111/jns.12244. Epub 2017 Nov 21.

PMID:
29119642
10.

Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study.

Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, Favejee MM, van der Meijden JC, Rizopoulos D, Brusse E, van Doorn PA, van der Ploeg AT, van der Beek NAME.

Neurology. 2017 Dec 5;89(23):2365-2373. doi: 10.1212/WNL.0000000000004711. Epub 2017 Nov 8.

PMID:
29117951
11.

Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.

Kuitwaard K, Fokkink WR, Brusse E, Vrancken AFJE, Eftimov F, Notermans NC, van der Kooi AJ, Merkies ISJ, Jacobs BC, van Doorn PA.

J Peripher Nerv Syst. 2017 Dec;22(4):425-432. doi: 10.1111/jns.12242. Epub 2017 Nov 21. Review.

PMID:
29092099
12.

Prediction of disease progression in Miller Fisher and overlap syndromes.

Verboon C, van Berghem H, van Doorn PA, Ruts L, Jacobs BC.

J Peripher Nerv Syst. 2017 Dec;22(4):446-450. doi: 10.1111/jns.12238. Epub 2017 Nov 15.

PMID:
29065229
13.

Small volume plasma exchange for Guillain-Barré syndrome in resource poor settings: a safety and feasibility study.

Islam MB, Islam Z, Rahman S, Endtz HP, Vos MC, van der Jagt M, van Doorn PA, Jacobs BC, Mohammad QD.

Pilot Feasibility Stud. 2017 Sep 29;3:40. doi: 10.1186/s40814-017-0185-0. eCollection 2017.

14.

The reduction of intraepidermal P2X3 nerve fiber density correlates with behavioral hyperalgesia in a rat model of nerve injury-induced pain.

Bechakra M, Schüttenhelm BN, Pederzani T, van Doorn PA, de Zeeuw CI, Jongen JLM.

J Comp Neurol. 2017 Dec 1;525(17):3757-3768. doi: 10.1002/cne.24302. Epub 2017 Aug 30.

PMID:
28815599
15.

Response to Herbert et al.

de Vries JM, Kuperus E, Hoogeveen-Westerveld M, Kroos MA, Wens SCA, Stok M, van der Beek NAME, Kruijshaar ME, Rizopoulos D, van Doorn PA, van der Ploeg AT, Pijnappel WWMP.

Genet Med. 2017 Nov;19(11):1283-1284. doi: 10.1038/gim.2017.49. Epub 2017 Jun 29. No abstract available.

PMID:
28661488
16.

Polyneuropathy relates to impairment in daily activities, worse gait, and fall-related injuries.

Hanewinckel R, Drenthen J, Verlinden VJA, Darweesh SKL, van der Geest JN, Hofman A, van Doorn PA, Ikram MA.

Neurology. 2017 Jul 4;89(1):76-83. doi: 10.1212/WNL.0000000000004067. Epub 2017 May 31.

PMID:
28566544
17.

Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Mahdi-Rogers M, Brassington R, Gunn AA, van Doorn PA, Hughes RA.

Cochrane Database Syst Rev. 2017 May 8;5:CD003280. doi: 10.1002/14651858.CD003280.pub5. Review.

PMID:
28481421
18.

European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience.

van der Ploeg AT, Kruijshaar ME, Toscano A, Laforêt P, Angelini C, Lachmann RH, Pascual Pascual SI, Roberts M, Rösler K, Stulnig T, van Doorn PA, Van den Bergh PYK, Vissing J, Schoser B; European Pompe Consortium.

Eur J Neurol. 2017 Jun;24(6):768-e31. doi: 10.1111/ene.13285. Epub 2017 May 6. Review.

PMID:
28477382
19.

High body mass and kidney dysfunction relate to worse nerve function, even in adults without neuropathy.

Hanewinckel R, Ikram MA, Franco OH, Hofman A, Drenthen J, van Doorn PA.

J Peripher Nerv Syst. 2017 Jun;22(2):112-120. doi: 10.1111/jns.12211.

PMID:
28429469
20.

International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome.

Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, Harbo T, Hartung HP, Hughes RAC, Kusunoki S, van Doorn PA, Willison HJ; IGOS Consortium.

J Peripher Nerv Syst. 2017 Jun;22(2):68-76. doi: 10.1111/jns.12209.

PMID:
28406555

Supplemental Content

Loading ...
Support Center